PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
31252559-5	2019	Furthermore, a strong reduction of the hexokinase II (HKII), phosphorylated form of PKM2 (at Tyr105 and Ser37) and lactate dehydrogenase A (LDH-A) was observed in response to imatinib along with a strong upregulation of mitochondrial complexes (OXPHOS).	Imatinib Mesylate	175-183	hexokinase 2	Homo sapiens	39-52	
31252559-5	2019	Furthermore, a strong reduction of the hexokinase II (HKII), phosphorylated form of PKM2 (at Tyr105 and Ser37) and lactate dehydrogenase A (LDH-A) was observed in response to imatinib along with a strong upregulation of mitochondrial complexes (OXPHOS).	Imatinib Mesylate	175-183	hexokinase 2	Homo sapiens	54-58	
29559564-10	2018	Overexpression of miR-202 sensitized imatinib resistant CML through the miR-202-mediated glycolysis inhibition by targetting HK2.	Imatinib Mesylate	37-45	hexokinase 2	Homo sapiens	125-128	
34738628-7	2022	The expression of glycolysis-related molecules (GLUT-1, hexokinase 2, pyruvate kinase M2 and lactate dehydrogenase) was assessed in parental and imatinib-resistant cells by western blotting, reverse transcription-quantitative PCR and glucose and lactate measurement kits.	Imatinib Mesylate	145-153	hexokinase 2	Homo sapiens	56-68	
34738628-12	2022	Although imatinib treatment downregulated GLUT-1 expression and other glycolysis pathway components hexokinase 2, pyruvate kinase M2, and lactate dehydrogenase in parental GIST-T1 cells even at low concentrations.	Imatinib Mesylate	9-17	hexokinase 2	Homo sapiens	100-112	
29559564-0	2018	Overexpression of miR-202 resensitizes imatinib resistant chronic myeloid leukemia cells through targetting Hexokinase 2.	Imatinib Mesylate	39-47	hexokinase 2	Homo sapiens	108-120